AstraZeneca Pharma India has received Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the Drugs Controller General of India for Osimertinib 40mg/80mg film coated tablets (Tagrisso&trade).

Osimertinib 40mg/80mg film coated tablets as monotherapy is now approved for additional indication for the adjuvant treatment after complete tumour resection in patients with non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.

The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets into a new disease area in India, subject to the receipt of related statutory approvals and licenses.

Powered by Capital Market - Live News

Net sales for Q3 FY21 stood at Rs 200.25 crore, a 10.5% fall over Rs 223.86 crore recorded in Q3 FY20. The result was announced after market hours yesterday, 8 February 2021.

Profit before tax fell 19.6% to Rs 28.30 crore in Q3 FY21 over Q3 FY20. Tax expense fell 12.1% to Rs 7.74 crore in Q3 FY21 over Q3 FY20.

AstraZeneca Pharma India is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease.

Powered by Capital Market - Live News

Net profit of Astrazeneca Pharma India declined 21.16% to Rs 21.05 crore in the quarter ended December 2020 as against Rs 26.70 crore during the previous quarter ended December 2019. Sales declined 10.55% to Rs 200.25 crore in the quarter ended December 2020 as against Rs 223.86 crore during the previous quarter ended December 2019.

Powered by Capital Market - Live News

Astrazeneca Pharma India will hold a meeting of the Board of Directors of the Company on 8 February 2021.

Powered by Capital Market - Live News